Full text is available at the source.
Abstract
Incretin-based therapies may improve quality of life and exercise tolerance while promoting weight loss in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).
- Randomized clinical trials indicate that glucagon-like peptide-1 receptor agonists can reduce symptoms and markers of heart failure severity.
- Incretin-based treatments may also decrease the risk of heart failure hospitalizations in this patient population.
- Exploratory analyses suggest that the mineralocorticoid receptor antagonist finerenone is associated with lower cardiovascular mortality and fewer worsening heart failure events across all body mass index levels.
- Greater benefits from finerenone are observed in patients with higher body mass indexes.
Simplified